Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
2 Biotech Stocks You'll Regret Not Buying on the Dip
02:00pm, Monday, 18'th Jul 2022 The Motley Fool
BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Time To Board The ARKK
06:53am, Friday, 08'th Jul 2022 Seeking Alpha
Yesterday I made a call that the Market bottomed on 6/16. Barchart's Trend Spotter has moved from Sell to Hold on ARKK.
Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High
01:00pm, Saturday, 25'th Jun 2022 The Motley Fool
Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High
09:00am, Saturday, 25'th Jun 2022
Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
BMO Initiates Coverage On This Gene Editing Spearhead
02:37pm, Friday, 17'th Jun 2022
BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentiall
5 Health Care Stocks Cathie Wood Favors
04:07pm, Thursday, 09'th Jun 2022
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
11:30am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR
CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-b
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 Update
04:49am, Monday, 06'th Jun 2022 Seeking Alpha
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.
Analyst Ratings for Intellia Therapeutics
09:39pm, Tuesday, 24'th May 2022 Benzinga
Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan
The Correction In Biopharmaceutical Stocks Is Likely Over
04:51am, Wednesday, 18'th May 2022 Seeking Alpha
Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. I highlight stocks that are attractively priced.
Why Editas Medicine's Shares Fell 28.9% This Week
03:52pm, Friday, 13'th May 2022 The Motley Fool
The company's progress for its lead therapy has been slow.
10 Biggest Price Target Changes For Monday
12:47pm, Monday, 09'th May 2022 Benzinga
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.
Oppenheimer cut the price target for Relmada T
